Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Allergic rhinitis - Management
View full scenario

How should I assess allergic rhinitis?

  • For symptoms of asthma and manage accordingly. For further information see the CKS topic on Asthma.
  • The most likely allergen causing allergic rhinitis:
    • The responsible allergen may be identifiable from the history — see Diagnosis.
    • Allergy testing to confirm the responsible allergen is indicated when burdensome allergen avoidance strategies, such as house dust mite avoidance measures, are being considered.
  • Factors influencing the choice of drug treatment to control allergic rhinitis.
    • Ask about:
      • Frequency and persistence of symptoms.
      • Subjective distress caused by symptoms and their adverse effect on aspects of daily life, such as sleep, recreation, and work.
      • Associated allergic conjunctivitis.
      • Personal preference for oral or intranasal treatments and the effectiveness of any previous treatments for allergic rhinitis.
    • Examine the nose if nasal blockage is a problem. Examine for nasal polyps, deviated nasal septum and mucosal swelling.
Basis for recommendation

These are pragmatic recommendations based on expert opinion.

  • Epidemiological studies have shown that allergic rhinitis is a risk factor for the development of asthma and usually precedes it. Optimal management of allergic rhinitis may improve coexisting asthma.

What treatment should I prescribe first-line for a person with allergic rhinitis?

  • For people who want an 'as-required' treatment for occasional symptoms, prescribe an antihistamine.
    • For people with allergic conjunctivitis, children less than 5 years of age, and people who prefer oral treatment, prescribe an oral antihistamine.
    • For all other people, prescribe intranasal azelastine.
  • For people who want preventive treatment to control more frequent or persistent symptoms explain the importance of regular treatment and good nasal spray/drop technique to control symptoms.
    • If the predominant symptom is nasal blockage or nasal polyps are present, prescribe an intranasal corticosteroid.
    • If the predominant symptoms are sneezing or nasal discharge, prescribe either an oral antihistamine or an intranasal corticosteroid. Explain the characteristics of antihistamines and intranasal corticosteroids and prescribe:
      • An antihistamine when oral treatment is preferred or allergic conjunctivitis is present.
      • An intranasal corticosteroid when more effective treatment is required.
    • If pregnant or breastfeeding prescribe an intranasal corticosteroid first-line.
      • If this is not tolerated or additional treatment is required, CKS recommends prescribing oral loratadine.
      • Intranasal sodium cromoglicate and nasal douching can be used as alternative or add on treatments.
    • If rapid relief of symptoms is required while awaiting preventive treatment to take effect:
      • If nasal congestion is a problem prescribe an intranasal decongestant for up to 7 days.
      • If using a intranasal corticosteroid, prescribe an oral antihistamine.
      • If symptoms are severe, impairing the quality of their life, prescribe a 5–10 day course of prednisolone 20–40 mg a day in adults, and 10 mg a day in children.
  • Advise people to reconsult after 2–4 weeks if symptoms remain inadequately controlled.

For a discussion on the comparative advantages and disadvantages of different treatment regimens, see Additional information.

Additional information
  • Table 1 shows some of the advantages and disadvantages of the different first-line drugs. These should be discussed with the person with allergic rhinitis when deciding which treatment to use.
Table 1. Key characteristics of different first-line treatment options.
 
Relative efficacy — allergic rhininitis
Relative efficacy — allergic conjunctivitis
Onset of action
Dose frequency
Intranasal antihistamine*
++
None
Within 15 minutes
Two to four times daily
Oral non-sedating antihistamine
++
++
Within 3 hours
Once-daily options available
Intranasal corticosteroids
+++
++
Within 12 hours
Once-daily options available
* Not suitable for children < 5 years of age.
† Maximum efficacy takes days or weeks to develop [ARIA, 2001a].

Basis for recommendation
  • Basis for recommending antihistamines for people preferring 'as-required' treatment for occasional symptoms:
    • This is a pragmatic recommendation supported by experts, based on evidence of the comparative speed of onset and efficacy of oral antihistamines compared with other treatments for allergic rhinitis.
  • Basis for recommending either an oral antihistamine or an intranasal corticosteroid for people who want regular treatment to control more frequent or persistent symptoms:
    • This is a pragmatic recommendation, based on evidence of the efficacy of intranasal corticosteroids and evidence of the efficacy of oral antihistamines to control the symptoms of allergic rhinitis.
  • Basis for treatment recommendations of pregnant and breastfeeding women [ARIA, 2001a; Scadding et al, 2008]:
    • Topical corticosteroids are recommended by experts in pregnancy and breastfeeding because their benefits are thought to outweigh their risks. Although there is a lack of safety data available in pregnant women with allergic rhinitis their use in pregnant women with asthma appears to be safe [Demoly et al, 2003].
    • Topical antihistamines are preferred to oral antihistamines by experts because they have a faster onset of action, minimal systemic absorption and do not expose the baby to potential adverse effects [ABPI Medicines Compendium, 2007].
    • The oral antihistamines chlorphenamine, loratadine and cetirizine are recommended by many experts for use in pregnancy if an oral antihistamine is required [Schaefer et al, 2007], and loratadine and cetirizine are recommended for use in breastfeeding [Schaefer et al, 2007]. CKS recommends loratadine because there is more safety data available than for cetirizine, and it is not associated with having the sedative properties of chlorphenamine.
    • Intranasal sodium cromoglicate is recommended by experts as an alternative treatment when other treatments are not acceptable. There is evidence that it is effective but because there are more effective alternatives it is not recommended first–line. However, it is the safest drug in the first 3 months of pregnancy.
  • The basis for recommending oral corticosteroids for severe symptoms:
    • This is a pragmatic recommendation supported by the consensus opinion of experts [ARIA, 2001a].
  • Basis for recommending use of intranasal decongestants:
  • Basis for not recommending sedating antihistamines, and depot corticosteroids [Scadding et al, 2008]:
    • Sedating antihistamines can affect a person's ability to drive or perform other skilled tasks, as well as impair academic and work ability, and they have no benefits over the newer non-sedating antihistamines available [BNF 54, 2007].
    • Depot corticosteroid injections are not recommended by experts because the risk–benefit profile for intramuscular corticosteroids is poor compared with other treatments available.

When and how should I give advice about avoiding allergens?

  • Advise allergen avoidance for people with:
    • Suspected pollen allergy.
    • House dust mite allergy when symptoms are inadequately controlled with maximal preventive drug treatment and the responsible allergen has been confirmed by allergy testing.
    • Suspected animal allergy after confirming the responsible allergen by allergen testing.
  • For people with:
    • Grass pollen allergen: advise avoiding walking in grassy open spaces, particularly during the early morning, evening, and night, when pollen counts are at their highest, and to keep windows shut in cars and buildings. Advise changing car pollen filters with each service, if these are fitted.
    • Confirmed house dust mite allergy inadequately controlled by drug treatment:
      • For people who want to try house dust mite avoidance measures, advise fitting mattresses and pillows with house dust mite impermeable covers; use synthetic pillows and acrylic duvets, and keep furry toys off the bed. Wash all bedding and furry toys at least once a week at high temperatures. If possible, choose wooden or hard floor surfaces instead of carpets. Blinds that can be wiped clean should be fitted instead of curtains. Surfaces should be wiped regularly with a clean, damp cloth.
    • Confirmed animal allergy: advise that ideally the animal should not be allowed in the house. When this is not acceptable, advise restricting their presence to the kitchen.
Basis for recommendation

These recommendations are based on expert opinion included in guidelines for the management of allergic rhinitis provided by the British Society for Allergy and Clinical Immunology [Scadding et al, 2008].

  • Recommendation on who to advise to try allergen avoidance:
    • House dust mite avoidance measures are not routinely recommended for all people with house dust mite allergy because the measures are inconvenient, expensive and there is a lack of good quality evidence for their effectiveness.
    • Avoidance of confirmed animal allergens is considered important to control symptoms of allergic rhinitis and reduce the risk of asthma developing.
  • Recommendations on how to avoid allergens:
    • There is a lack of good-quality trials examining the effect of house dust mite avoidance techniques in controlling the symptoms of allergic rhinitis.
    • A Cochrane review of allergen avoidance techniques in the control of perennial allergic rhinitis found [Sheikh et al, 2007b]:
      • Seven relevant randomized controlled trials, of which two trials were of good quality and five small trials were of poor quality.
      • Of the interventions investigated, the authors found limited evidence that the use of acaricides and extensive bedroom-based environmental control programs may reduce symptoms of perennial allergic rhinitis caused by house dust mite.

What follow-up advice can I give to someone on treatment with well-controlled symptoms of allergic rhinitis?

  • Advise people who have achieved adequate control of their symptoms with drug treatment that they should continue with treatment until they are no longer likely to be exposed to the suspected allergen:
    • For people allergic to house dust mites and people allergic to pets that remain in their homes, symptoms are usually present throughout the year, requiring ongoing treatment.
    • For people allergic to tree pollens, treatment is usually required from early to late spring.
    • For people allergic to grass pollens, treatment is usually required from late spring to early summer.
  • Advise people who have recurrent episodes of allergic rhinitis controlled by intranasal corticosteroids to restart treatment at least 7 days before re-exposure to allergen. When the time of re–exposure to antigen is uncertain, such as the start of the pollination season, start treatment several weeks before the most likely time of re–exposure.
Basis for recommendation

These recommendations are from expert opinion and are pragmatic in nature [ARIA, 2001b].

Prescriptions

Non-sedating oral antihistamines

Age from 2 years to 5 years 11 months
Cetirizine s/f solution: 5mg once a day
Cetirizine 1mg/ml oral solution sugar free
Take one 5ml spoonful once a day.
Supply 150 ml.
Age: from 2 years to 5 years 11 months
NHS cost: £3.83
OTC cost: £6.25
Licensed use: yes
Loratadine syrup: 5mg once a day
Loratadine 5mg/5ml oral solution
Take one 5ml spoonful once a day.
Supply 150 ml.
Age: from 2 years to 5 years 11 months
NHS cost: £7.95
OTC cost: £4.99
Licensed use: yes
Age from 6 years to 11 years 11 months
Cetirizine s/f solution: 10mg once a day
Cetirizine 1mg/ml oral solution sugar free
Take two 5ml spoonfuls once a day.
Supply 300 ml.
Age: from 6 years to 11 years 11 months
NHS cost: £7.65
OTC cost: £8.90
Licensed use: yes
Loratadine syrup: 10mg once a day
Loratadine 5mg/5ml oral solution
Take two 5ml spoonfuls once a day.
Supply 300 ml.
Age: from 6 years to 11 years 11 months
NHS cost: £15.90
OTC cost: £9.98
Licensed use: yes
Age from 12 years onwards
Cetirizine tablets: 10mg once a day
Cetirizine 10mg tablets
Take one tablet once a day.
Supply 28 tablets.
Age: from 12 years onwards
NHS cost: £0.47
OTC cost: £2.68
Licensed use: yes
Loratadine tablets: 10mg once a day
Loratadine 10mg tablets
Take one tablet once a day.
Supply 28 tablets.
Age: from 12 years onwards
NHS cost: £0.94
OTC cost: £6.99
Licensed use: yes
Fexofenadine tablets: 120mg once a day
Fexofenadine 120mg tablets
Take one tablet once a day.
Supply 30 tablets.
Age: from 12 years onwards
NHS cost: £6.23
Licensed use: yes

Intranasal antihistamine

Age from 5 years onwards
Azelastine 140microgram (0.1%) nasal spray
Azelastine 140micrograms/actuation nasal spray
Spray once into each nostril twice a day when required.
Supply 1 spray.
Age: from 5 years onwards
NHS cost: £11.09
Licensed use: yes

Intranasal corticosteroid sprays

Age from 4 years to 11 years 11 months
Fluticasone 50microgram nasal spray (4 years to 11 years 11 months)
Fluticasone 50micrograms/actuation nasal spray
Spray once into each nostril each morning.
Supply 1 spray.
Age: from 4 years to 11 years 11 months
NHS cost: £11.69
Licensed use: yes
Patient information: If the symptoms are not controlled the dose may be increased to a maximum of one spray into each nostril twice a day. If the symptoms are controlled then continue with one spray into each nostril each morning.
Age from 5 years to 13 years 11 months
Flunisolide 25microgram nasal spray (5 years to 13 years 11 months)
Flunisolide 25micrograms/actuation nasal spray
Spray once into each nostril up to three times a day.
Supply 1 spray.
Age: from 5 years to 13 years 11 months
NHS cost: £5.05
Licensed use: yes
Age from 6 years to 11 years 11 months
Mometasone 50microgram nasal spray (6 years to 11 years 11 months)
Mometasone 50micrograms/actuation nasal spray
Spray once into each nostril once a day.
Supply 1 spray.
Age: from 6 years to 11 years 11 months
NHS cost: £7.83
Licensed use: yes
Triamcinolone 55microgram nasal spray (6 years to 11 years 11 months)
Triamcinolone 55micrograms/actuation nasal spray
Spray once into each nostril once a day.
Supply 1 spray.
Age: from 6 years to 11 years 11 months
NHS cost: £7.39
Licensed use: yes
Patient information: If the symptoms are not controlled, the dose may be increased to a maximum of two sprays into each nostril once a day. Then when controlled, reduce the dose back to one spray into each nostril once a day.
Age from 6 years onwards
Beclometasone 50microgram nasal spray
Beclometasone 50micrograms/actuation nasal spray
Spray twice into each nostril twice a day.
Supply 1 spray.
Age: from 6 years onwards
NHS cost: £4.35
Licensed use: yes
Patient information: If the symptoms are not controlled, the dose may be increased to a maximum of four sprays into each nostril twice a day (or two sprays into each nostril four times a day). If the symptoms are controlled, then the dose may be reduced to one spray into each nostril twice a day.
Age from 12 years onwards
Budesonide 64microgram nasal spray
Budesonide 64micrograms/actuation nasal spray
Spray once into each nostril twice a day.
Supply 1 spray.
Age: from 12 years onwards
NHS cost: £4.49
Licensed use: yes
Patient information: If the symptoms are not controlled, continue with one spray into each nostril twice a day. If the symptoms are controlled, then the dose may be reduced to one spray into each nostril once a day.
Fluticasone 50microgram nasal spray (12 years onwards)
Fluticasone 50micrograms/actuation nasal spray
Spray twice into each nostril each morning.
Supply 1 spray.
Age: from 12 years onwards
NHS cost: £11.69
Licensed use: yes
Patient information: If the symptoms are not controlled the dose may be increased to a maximum of two spray into each nostril twice a day. If the symptoms are controlled then continue with one spray into each nostril each morning.
Mometasone 50microgram nasal spray (12 years onwards)
Mometasone 50micrograms/actuation nasal spray
Spray twice into each nostril once a day.
Supply 1 spray.
Age: from 12 years onwards
NHS cost: £7.83
Licensed use: yes
Patient information: If the symptoms are not controlled, the dose may be increased to a maximum of four sprays into each nostril once a day. If the symptoms are controlled, then the dose may be reduced to one spray into each nostril once a day.
Triamcinolone 55microgram nasal spray (12 years onwards)
Triamcinolone 55micrograms/actuation nasal spray
Spray twice into each nostril once a day.
Supply 1 spray.
Age: from 12 years onwards
NHS cost: £7.39
Licensed use: yes
Patient information: When the symptoms are controlled then the dose may be reduced to one spray into each nostril once a day.
Age from 14 years onwards
Flunisolide 25microgram nasal spray (14 years onwards)
Flunisolide 25micrograms/actuation nasal spray
Spray twice into each nostril twice a day.
Supply 1 spray.
Age: from 14 years onwards
NHS cost: £5.05
Licensed use: yes
Patient information: If the symptoms are not controlled, the dose may be increased to a maximum of two sprays into each nostril three times a day. If the symptoms are controlled, then the dose may be reduced to one spray into each nostril twice a day.

Intranasal corticosteroid drops

Age from 2 years onwards
Betamethasone 0.1% nose drops
Betamethasone 0.1% ear/eye/nose drops
Put two drops into each nostril twice a day.
Supply 10 ml.
Age: from 2 years onwards
NHS cost: £2.32
Licensed use: yes
Patient information: If the symptoms are controlled then the dose may be reduced to one drop into each nostril once a day. In people 12 years old and over, if the symptoms are not controlled, the dose may be increased to a maximum of two drops into each nostril three times a day.
Age from 16 years onwards
Fluticasone 400microgram nose drops
Fluticasone 400microgram unit dose nasal drops
Put six drops into each nostril once or twice a day.
Supply 28 ml.
Age: from 16 years onwards
NHS cost: £13.79
Licensed use: yes

Oral steroid course: children

Age from 2 years to 11 years 11 months
Prednisolone soluble tablets: 10mg each morning for 5 days
Prednisolone 5mg soluble tablets
Take two tablets each morning (as a single dose) for 5 days.
Supply 10 tablets.
Age: from 2 years to 11 years 11 months
NHS cost: £1.43
Licensed use: yes
Prednisolone soluble tablets: 10mg each morning for 7 days
Prednisolone 5mg soluble tablets
Take two tablets each morning (as a single dose) for 7 days.
Supply 14 tablets.
Age: from 2 years to 11 years 11 months
NHS cost: £1.99
Licensed use: yes
Prednisolone soluble tablets: 10mg each morning for 10 days
Prednisolone 5mg soluble tablets
Take two tablets each morning (as a single dose) for 10 days.
Supply 40 tablets.
Age: from 2 years to 11 years 11 months
NHS cost: £2.35
Licensed use: yes

Oral steroid course: adults

Age from 16 years onwards
Prednisolone e/c tablets: 30mg each morning for 5 days
Prednisolone 5mg gastro-resistant tablets
Take six tablets each morning (as a single dose) for 5 days.
Supply 30 tablets.
Age: from 16 years onwards
NHS cost: £3.88
Licensed use: yes
Prednisolone tablets: 30mg each morning for 5 days
Prednisolone 5mg tablets
Take six tablets each morning (as a single dose) for 5 days.
Supply 30 tablets.
Age: from 16 years onwards
NHS cost: £0.66
Licensed use: yes
Prednisolone e/c tablets: 30mg each morning for 7 days
Prednisolone 5mg gastro-resistant tablets
Take six tablets each morning (as a single dose) for 7 days.
Supply 42 tablets.
Age: from 16 years onwards
NHS cost: £13.04
Licensed use: yes
Prednisolone tablets: 30mg each morning for 7 days
Prednisolone 5mg tablets
Take six tablets each morning (as a single dose) for 7 days.
Supply 42 tablets.
Age: from 16 years onwards
NHS cost: £1.55
Licensed use: yes
Prednisolone e/c tablets: 30mg each morning for 10 days
Prednisolone 5mg gastro-resistant tablets
Take six tablets each morning (as a single dose) for 10 days.
Supply 60 tablets.
Age: from 16 years onwards
NHS cost: £18.63
Licensed use: yes
Prednisolone tablets: 30mg each morning for 10 days
Prednisolone 5mg tablets
Take six tablets each morning (as a single dose) for 10 days.
Supply 60 tablets.
Age: from 16 years onwards
NHS cost: £2.21
Licensed use: yes

Sodium cromoglicate (to consider in children/pregnant women)

Age from 2 years onwards
Sodium cromoglicate 4% nasal spray
Sodium cromoglicate 4% nasal spray
Spray once into each nostril 2 to 4 times a day.
Supply 1 spray.
Age: from 2 years onwards
NHS cost: £17.76
Licensed use: yes

Intranasal decongestants - for nasal blockage (short term)

Age from 2 years onwards
Ephedrine 0.5% nose drops
Ephedrine 0.5% nasal drops
Put one to two drops into each nostril up to four times a day when required for nasal blockage. Do not use for more than 7 days.
Supply 10 ml.
Age: from 2 years onwards
NHS cost: £1.25
Licensed use: yes
Age from 6 years to 11 years 11 months
Xylometazoline 0.05% nose drops
Xylometazoline 0.05% nasal drops
Put one to two drops into each nostril once or twice a day when required for nasal blockage. Do not use for more than 7 days.
Supply 10 ml.
Age: from 6 years to 11 years 11 months
NHS cost: £1.59
Licensed use: yes
Age from 12 years onwards
Xylometazoline 0.1% nose drops
Xylometazoline 0.1% nasal drops
Put two to three drops into each nostril 2 to 3 times a day when required for nasal blockage. Do not use for more than 7 days.
Supply 10 ml.
Age: from 12 years onwards
NHS cost: £1.91
Licensed use: yes
Xylometazoline 0.1% nasal spray
Xylometazoline 0.1% nasal spray
Spray once into each nostril 2 to 3 times a day when required for nasal blockage. Do not use for more than 7 days.
Supply 10 ml.
Age: from 12 years onwards
NHS cost: £1.91
Licensed use: yes

© NHS Institute for Innovation and Improvement